论文部分内容阅读
目的探讨丁苯酞软胶囊治疗急性脑梗死(ACI)的临床疗效。方法选取2011年3月—2012年3月无锡市第二人民医院神经内科收治的ACI患者80例,按随机数字表法分为对照组与研究组,各40例。对照组患者予以常规治疗,研究组患者在对照组基础上予以丁苯肽软胶囊治疗。观察两组患者病情进展情况、治疗前后美国国立卫生院卒中量表(NIHSS)评分及不良反应发生情况。结果研究组患者病情进展率低于对照组,差异有统计学意义(P<0.05);治疗前两组患者NIHSS评分比较,差异无统计学意义(P>0.05),治疗后研究组患者NIHSS评分低于对照组,差异有统计学意义(P<0.05);两组患者均未发生严重不良反应。结论丁苯肽软胶囊治疗ACI的临床疗效显著,可抑制患者病情进展,改善患者神经功能,且不良反应少,安全性高。
Objective To investigate the clinical efficacy of butylphthalide soft capsule in the treatment of acute cerebral infarction (ACI). Methods Eighty ACI patients admitted to Department of Neurology, Second People ’s Hospital of Wuxi from March 2011 to March 2012 were divided into control group and study group according to random number table method, 40 cases each. Patients in the control group were treated routinely, and patients in the study group were treated with butanlin capsule on the basis of the control group. Observe the progress of the two groups of patients, before and after treatment, the National Institutes of Health Stroke Scale (NIHSS) score and adverse reactions. Results The progression rate of the study group was lower than that of the control group (P <0.05). There was no significant difference in the NIHSS scores between the two groups before treatment (P> 0.05). After treatment, the NIHSS score Lower than the control group, the difference was statistically significant (P <0.05); two groups of patients had no serious adverse reactions. Conclusion The clinical efficacy of DBT soft capsule in the treatment of ACI is significant, which can inhibit the progression of the disease and improve the neurological function of patients with less adverse reactions and high safety.